Introducing the Next Generation Drug Discovery Platforms


Newormics is a developer of the first high-throughput, high-content drug screening platforms for use with in vivo small animal models as well as 3D tissue organoids. The company provides microfluidics-based platforms to advance early stage drug discovery and toxicity studies for faster and better drug development with cost-effective solutions. Newormics is co-founded by Prof. Adela Ben-Yakar, and Evan Hegarty from the Mechanical Engineering Department at the University of Texas at Austin.